menu
    • menu
    [{"orgOrder":0,"company":"GENESIS Pharma","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"GENESIS Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GENESIS Pharma \/ Deciphera Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"GENESIS Pharma \/ Deciphera Pharmaceuticals"},{"orgOrder":0,"company":"GENESIS Pharma","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"GENESIS Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GENESIS Pharma \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"GENESIS Pharma \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"GENESIS Pharma","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Vamorolone","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GENESIS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GENESIS Pharma \/ GENESIS Pharma","highestDevelopmentStatusID":"14","companyTruncated":"GENESIS Pharma \/ GENESIS Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by GENESIS Pharma

    Menu

    GENESIS Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GENESIS Pharma

                            Greece arrow
                            2024 ACI Convention
                            Not Confirmed

                            GENESIS Pharma

                            Greece arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vamorolone

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : Santhera Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Santhera Signs Exclusive AGAMREE® Distribution Deal with GENESIS Pharma

                            Details : Santhera's agreement with GENESIS Pharma for Agamree (vamorolone) to commercialize in 20 markets in Central and Eastern Europe. It is indicated for the treatment of Duchenne muscular dystrophy.

                            Brand Name : Agamree

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 10, 2024

                            Lead Product(s) : Vamorolone

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : Santhera Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GENESIS Pharma

                            Greece arrow
                            2024 ACI Convention
                            Not Confirmed

                            GENESIS Pharma

                            Greece arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cemiplimab

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GENESIS Pharma Signs Distribution Agreement with Regeneron for Cemiplimab

                            Details : Under the agreement, GENESIS will commercialize Libtayo (cemiplimab), which is a PD-1 inhibitor. It is used for the treatment of advanced basal cell carcinoma, cutaneous squamous cell carcinoma.

                            Brand Name : Libtayo

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 01, 2024

                            Lead Product(s) : Cemiplimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            GENESIS Pharma

                            Greece arrow
                            2024 ACI Convention
                            Not Confirmed

                            GENESIS Pharma

                            Greece arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ripretinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Deciphera Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GENESIS Pharma Announces Distribution Agreement with Deciphera for RIPRETINIB in EU

                            Details : Under the terms of the agreement, GENESIS Pharma will exclusively commercialize Qinlock (ripretinib) for the treatment of fourth-line gastrointestinal stromal tumor.

                            Brand Name : Qinlock

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 12, 2024

                            Lead Product(s) : Ripretinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Deciphera Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth